Vapotherm, Inc. (VAPO)
Stock Price:
$30.14 USD
-0.64 (-2.06%)
Updated Oct 20, 2020 3:53 PM EDT - Market open
Key Info
| Market Cap |
770.56M |
| Revenue (ttm) |
78.09M |
| Net Income (ttm) |
-47.09M |
| Shares Out |
25.57M |
| EPS (ttm) |
-2.23 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 20, 2020 |
| Last Price |
$30.14 |
| Previous Close |
$30.77 |
| Change ($) |
-0.64 |
| Change (%) |
-2.06% |
| Day's Open |
30.62 |
| Day's Range |
30.01 - 31.73 |
| Day's Volume |
352,426 |
| 52-Week Range |
6.86 - 54.42 |
More Stats
| Market Cap |
770.56M |
| Enterprise Value |
666.78M |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
25.57M |
| Float |
14.29M |
| EPS (basic) |
-2.24 |
| EPS (diluted) |
-2.23 |
| FCF / Share |
-2.25 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.34M |
| Short Ratio |
4.53 |
| Short % of Float |
16.37% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
9.87 |
| PB Ratio |
5.47 |
| Revenue |
78.09M |
| Operating Income |
-43.84M |
| Net Income |
-47.09M |
| Free Cash Flow |
-51.87M |
| Net Cash |
103.78M |
| Net Cash / Share |
4.06 |
| Gross Margin |
27.29% |
| Operating Margin |
-56.15% |
| Profit Margin |
-60.30% |
| FCF Margin |
-66.43% |
| ROA |
-18.70% |
| ROE |
-55.96% |
| ROIC |
-61.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$47.33*
(57.06% upside)
Low
43.0
Current: $30.14
High
54.0
Target: 47.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 48.10 | 42.38 | 35.60 | 30.12 |
| Revenue Growth | 13.51% | 19.05% | 18.18% | - |
| Gross Profit | 21.31 | 16.77 | 13.24 | 9.94 |
| Operating Income | -48.16 | -37.23 | -28.87 | -22.22 |
| Net Income | -51.06 | -42.47 | -31.01 | -23.07 |
| Shares Outstanding | 18.60 | 2.91 | 0.69 | 0.47 |
| Earnings Per Share | -2.74 | -14.65 | -44.82 | -49.38 |
| Operating Cash Flow | -39.66 | -40.02 | -29.25 | -25.37 |
| Capital Expenditures | -4.75 | -5.18 | -5.95 | -4.53 |
| Free Cash Flow | -44.41 | -45.20 | -35.19 | -29.90 |
| Cash & Equivalents | 73.51 | 60.02 | 28.36 | 7.83 |
| Total Debt | 45.28 | 34.48 | 21.95 | 11.95 |
| Net Cash / Debt | 28.23 | 25.54 | 6.41 | -4.13 |
| Assets | 112 | 97.25 | 60.24 | 30.86 |
| Liabilities | 58.15 | 45.69 | 34.46 | 19.49 |
| Book Value | 53.74 | 51.56 | -127 | -96.27 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Vapotherm, Inc. |
| Country |
United States |
| Employees |
279 |
| CEO |
Joseph F. Army |
Stock Information
| Ticker Symbol |
VAPO |
| Stock Exchange |
New York Stock Exchange |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NYSE: VAPO |
| IPO Date |
November 14, 2018 |
Description
Vapotherm, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; tracheostomy adaptors; and ProSoft cannula to provide gentle contact with the skin. In addition, Vapotherm, Inc. offers aerosol disposable patient circuit that is designed to streamline the provision of intermittent and continuous aerosol nebulization by limiting condensate management; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is based in Exeter, New Hampshire.